Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.
According to a study presented at the American College of Rheumatology (ACR) Convergence 2025, early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) when aged 2 years or less leads to significant and sustained improvements in disease activity.
Using data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023, researchers aimed to describe the demographic and disease characteristics of children diagnosed with non-sJIA when aged from 0 to 23 months.
The study found that outcomes were comparable to patients who received treatment later in life and those not exposed to TNF inhibitors.
No direct quote available in the text.
Author's summary: Early TNF inhibitor use improves non-sJIA outcomes.
More News
- iOS 26.1 Coming Soon: New Features for Your iPhone and Release Date
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Pangilinan says Meralco on track to hit P50-billion profit target - BusinessWorld Online
- Canada's youth facing growing opioid crisis: Calls for urgent action
- Elon Musk could step down if Tesla pay plan is rejected
- 2 US Navy aircraft crash in South China Sea
- Meralco profit jumps 14% to P40 billion in 9 months
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado